Meeting
2018 ASCO Annual Meeting
Survival of patients treated by a Precision Oncology approach is determined by performance status and lines of therapy.
Authors
Bat-Ami Gordon
Sylvester Comprehensive Cancer Center, Miami, FL
Bat-Ami Gordon , Jared Cotta , Jonathan C. Trent II
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Citation
J Clin Oncol 36, 2018 (suppl; abstr 12071)
DOI
10.1200/JCO.2018.36.15_suppl.12071
Abstract #
12071
Poster Bd #
184
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Genomic landscape and therapeutic implications in advanced solid cancers: KOSMOS-II (KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors, KCSG AL-22-09).
First Author: Heejung Chae
Poster
2022 ASCO Quality Care Symposium
Implementation of a virtual, on-demand, molecular tumor board at a large, multi-clinic, community oncology practice.
First Author: Andrew Jacob McKenzie
Poster
2019 ASCO Annual Meeting
Can pediatric and adolescent patients with recurrent tumors benefit from a precision medicine program? The European MAPPYACTS experience.
First Author: Pablo Berlanga
Poster
2024 ASCO Annual Meeting
Genomics to select treatment for patients (pts) with metastatic cancer: Final analysis of Molecular Tumor Board (MTB) evaluations in the ROME trial.
First Author: Andrea Botticelli